Consider Best Sequencing of Agents When Treating Patients With Neuroendocrine Tumors

Mei Ka Fong, PharmD, BCOP, said that although many potential adverse events are well understood in patients receiving traditional treatments, there are no studies investigating the sequencing of these agents.

In an interview with Pharmacy Times about her presentation at the North American Neuroendocrine Tumor Society (NANETS) 2021 neuroendocrine tumor (NET) Medical Symposium, Mei Ka Fong, PharmD, BCOP, said it is important to consider the best sequencing of various agents when treating patients with NETs.

In the interview, Fong said that although many potential adverse events are well understood in patients receiving traditional treatments, there are no studies investigating the sequencing of these agents. Therefore, the adverse event profile may vary depending on where the therapy falls in the patients' lines of therapy.